Summary
The aim of the study was to compare the pulmonary effects of four beta-blockers with different ancillary properties: propranolol (non-beta1 selective without ISA), oxprenolol (non-beta1 selective with ISA), atenolol (beta1 selective), and celipropol (beta1 selective with mild beta2-agonist and alpha2-antagonist activity) in hypertensive patients with chronic obstructive lung disease. Ten asthmatic patients, all males, aged 50–66 years were studied. Entry criteria were a) DBP≧95 mmHg and ≦115 mmHg; b) FEV1<70% of the theoretical values; c) FEV1 increase of at least 20% after salbutamol inhalation (200 μg). After a 2-week washout period on placebo, each patient received propranolol (80 mg/day), oxprenolol (80 mg/day), atenolol (100 mg/day), and celiprolol (200 mg/day) for 1 week, according to a randomized, cross-over design. At the end of the washout and of each treatment period, airway function, assessed by FEV1, FVC, and FEV1%, was evaluated by spirometry both in the basal condition and after salbutamol inhalation. Unlike propranolol and oxprenolol, which significantly reduced FEV1 and inhibited the bronchdilator response to inhaled salbutamol, atenolol and celiprolol did not significantly affect respiratory function and did not antagonize salbutamol effects. Celiprolol more closely approached placebo in its respiratory effects than did atenolol, although the differences were not statistically significant.
Similar content being viewed by others
References
McNeil RS. Effect of a beta-adrenergic blocking agent, propranolol, on asthmatics.Lancet 1964;2:1101–1102.
McNeil RS, Ingram CG. Effect of propranolol on ventilatory function.Am J Cardiol 1966;18;473–475.
Nordstrom LA, MacDonald F, Gobel FL. The effect of propranolol on respiratory function and exercise tolerance in patients with chronic obstructive lung disease.Chest 1975;67:287–292.
Zaid G, Beall GN. Bronchial response to beta-adrenergic blockade.N Engl J Med 1966;275:580–584.
Dorow P. Einfuhrung. In: Dorow P. Ed.Beta-blockade und atemwegsfunction Pneumologishes Kolloquium, H295, Berlin: Walter de Dryter, 1985:1–10.
McDevitt DG. Beta-adrenoceptor antagonists and respiratory function.Br J Clin Pharmacol 1978;5:97–99.
Anderson EG, Calcraft B, Jarawalla AG, Al-Zaiback N. Persistent asthma after treatment with beta blocking drugs.Br J Dis Chest 1979;73:407–408.
Raine JM, Palazzo MG, Kerr JH, Sleight P. Near fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane.Br Med J 1981; 282;548–549.
Lofdahl CG, Svedmyr N. Cardioselectivity of atenolol and metoprolol. A study in asthmatic patients.Eur J Respir Dis 1981;62:396–404.
Lawrence DS, Sahay JN, Chatterjee SS, Cruickshank JM. Beta-blockers and asthma.Drugs 1983;25(Suppl 2):232–236.
Kendall MJ, John VA, Quarterman CP, Welling PG. A single and multiple dose pharmacokinetic and pharmacodynamic comparision of conventional and slow release metoprolol.Eur J Clin Pharmacol 1980;17:87–92.
Cruickshank JM. The clinical importance of cardioselectivity and lipophilicity in beta-blockers.Am Heart J 1980;100:160P-178.
Formgren H. The effect of metoprolol and practolol on lung function and blood pressure in hypertensive asthmatics.Br J Clin Pharmacol 1976;3:1007–1011.
Dorow P, Bethge H, Tonnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in non-asthmatic chronic obstructive lung disease and angina pectoris.Eur J Clin Pharmacol 1986;31:143–147.
Chang LTC. Use of practolol in asthmatic: A plea for caution.Lancet 1971;2:321.
Wall Manning HJ, Simpson FO. Practical treatment in asthmatics.Lancet 1971;2:1264–1205.
Decalmer PB, Chatterjee S, Cruickshank JM, et al. Beta-blockers and asthma.Br Heart J 1978;40:184–189.
Oh UM, Kaye CM, Warrington SJ, et al. Studies of cardioselectivity and partial agonist activity in beta-adrenoceptor blockade effects on heart rate and peak expiratory flow rate during exercise.Br J Clin Pharmacol 1978;5:107–120.
Garrad GS. The effects of conventional and slow-release oxprenolol on airways function, in normal subjects. In: Judd J, ed.Topics in cardiovascular disease. Symposium Basle 1976, Ciba, Horsham England, 1977:157.
Macdonald AG, McNeill RS. A comparison of the effect on airway resistance of a new beta-blocking drug ICI.50,172 and propranolol.Br J Anaesthesia 1968;40:508–510.
Beumer HM. Adverse effects of beta-adrenergic receptor blocking drugs on respiratory function.Drugs 1974;7:13–138.
Paterson JW. Beta-adrenergic blocking drugs.Br Med J 1971;2:652.
Christensen CC, Boye NP. Erikson H, Hansen G. Influence of pindolol (Visken) on respiratory function in 20 asthmatic patients.Eur J Clin Pharmacol 1978;13:9–12.
Ruffin RE, McIntyre EL, Latimer KM, et al. Assessment of beta-adrenoceptor antagonists in asthmatic patients.Br J Clin Pharmacol 1982;13:325S-335S.
Lammers JW, Folgering M, Van Herwaarden CL. Ventilatory effects of long-term treatment with pindolol and metoprolol in hypertensive patients with chronic obstructive lung disease.Br J Clin Pharmacol 1985;20:205–210.
Brown R, Slutsky A, Doshan HD, et al. The effect of celiprolol, a bronchosparing cardioselective beta1-alpha2-adrenoceptor blocking agent in asthma.Circulation 1984;70 (Suppl II):382.
Hitzenberger G. Celiprolol, clinical dosage, efficacy an safety in asthmatic and elderly patients.Br J Clin Pract 1985;29(Suppl 40):25–32.
Matthys H, Pohl M, Braig H, Ruhle KH. The cardiopulmonary effects of celiprolol and propranolol in asymptomatic bronchial asthmatics.Br J Clin Pract 1985;39(Suppl 40):33.
Matthys H, Doshan HD, Ruhle KH, et al. Bronchopsaring properties of celiprolol, a new beta1, alpha2-blocker, in propranolol sensitive asthmatic patients.J Cardidovasc Pharmacol 1986;8(Suppl 40):40–43.
Rosenthal RR, Doshan HD, Applin WJ, Caruso FS. Celiprolol: An investigation of a new beta1-alpha2-adrenoceptor antagonist in asthmatic patients.Br J Clin Pract 1985;39(Suppl 40):34–36.
Capone P, Mayol R. A comparative study of celiprolol and placebo in the treatment of hypertension.Br J Clin Pract 1985;39(Suppl 40):65–69.
Dorow P, Clauzel AM, Capone P, et al. A comparison of celiprolol and chlorthalidone in hypertensive patients with reversible bronchial obstruction.J Cardiovasc Pharmacol 1986;8:102–104.
Bruschi C, Casali L, Cerveri I, et al. effects of celiprolol on the bronchial reactivity in asthma.Am J Cardiol 1988;61:53C-54C.
Doshan H, Brown R, Applin WJ, etal. Effects of high doses of celiprolol in asthmatic patients.J Cardiovasc Pharmacol 1986;8(Suppl 4):109–111.
Dorow P. Celiprolol—Review of airways studies.Am J Cardiol 1988;61:23C-26C.
Doshan HD, Rosenthal RR, Brown R, et al. Celiprolol, atenolol and propranolol: A comparison of pulmonary effects in asthmatic patients.J Cardiovasc Pharmacol 1986;8 (Suppl 4):105–108.
Van Zyl AI, Jennings AA, Bateman ED, Opie LH. Comparison of respiratory effects of two cardioselective betablockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension.Chest 1989;95;209–213.
Van Inwegen RG, Khandwala A, Ingram R, et al. Effects of celiprolol on the interactions of serotonin (5HT) and postsynaptic alpha2-receptors in isolated cat tracheal rings.Fed Proc 1984;43:745.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fogari, R., Zoppi, A., Tettamanti, F. et al. Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease. Cardiovasc Drug Ther 4, 1145–1149 (1990). https://doi.org/10.1007/BF01856511
Issue Date:
DOI: https://doi.org/10.1007/BF01856511